COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
A new collaboration between the Morehouse School of Medicine (MSM) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to enhance diversity of cancer patients included in proteogenomic studies.
Facilitated by the Frederick National Laboratory for Cancer Research (FNLCR), the...
The following is the first entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss molecular and computational techniques in biology with Natalie Clark, PhD from the Proteomics Platform at the Broad...
The National Cancer Institute (NCI) and Lund University in Sweden are pleased to announce the signing of an extension to their memorandum of understanding (MOU) for proteogenomics cancer research. The MOU, involving NCI’s International Cancer Proteogenome Consortium (ICPC) and Clinical Proteomic...
Intrahepatic cholangiocarcinomas (iCC) pose a diagnostic and treatment challenge due to their rarity and inter/intrapatient heterogeny.
Proteogenomic characterization of patient tissues has enriched our understanding of liver cancer, uncovering potential therapeutic targets, new subtypes, and offering hope for more effective treatments. However, there remains a gap in translating these findings into clinical practice.
The Cancer Imaging Archive (TCIA), managed by the National Cancer Institute's Cancer Imaging Program (CIP), collects, curates, and hosts digital histopathology and standard-of-care radiology imaging from CPTAC-enrolled patients to provide data for imaging-omics research. Algorithmic analysis of...
Recent strides in the field of genomics, exemplified by initiatives like The Cancer Genome Atlas (TCGA), have illuminated the genetic landscape of endometrial carcinoma (EC). The identification of four distinct EC...
Researchers from the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) have produced a resource of global proteomic and post-translational modifications, whole genome and whole exome sequencing, miRNA and totalRNA sequencing, DNA methylation, imaging, and clinical...
In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...
Recently published in Nature Communications, PepQuery2 is a powerful tool that facilitates fast and targeted identification of both new and existing peptides in proteomics datasets obtained from mass spectrometry experiments. It...
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative...
The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted...
The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration...
Glycosylation is a ubiquitous type of protein modification that is associated with biological functions and diseases, including cancer. Often found on cell surface or secreted into circulation, glycoproteins can be leveraged for diagnosis and treatment.
Clear cell renal cell carcinoma (ccRCC) is a common type of kidney cancer that originates from the cells of the renal tubules. Recent research has focused on identifying tumor-cell-specific markers to provide mechanistic insights into cancer etiology and support the development of novel targeted...
Despite unprecedented advances in the development of targeted- and immuno-therapies for various cancer types, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related death worldwide. A comprehensive characterization of PDAC is critical for the development of new therapies...
Despite extensive clinical and scientific efforts, pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in Korea and around the world. Prior analyses of PDAC tissues have identified key genomic features of the disease, but proteomic signatures have not...
Diffuse intrinsic pontine gliomas (DIPG) are a type of brain tumor that is extremely aggressive and have a historically poor prognosis. To improve these outcomes, the development of novel therapies and methods to measure their efficacy are critical.
Renal cell carcinoma (RCC) is among the ten most diagnosed cancers worldwide for men and women and comprises a wide array of histologically and genetically defined subtypes involving the kidney. Clear cell RCC (ccRCC) accounts for ~75% of all RCC cases and the majority of renal cancer-associated...
